PRKAA1 and breast carcinoma: The mTORC1/p70S6K signaling is a known critical regulator of energy metabolism (74) and we previously demonstrated that its inhibition, associated with a persistent activation of AMPK, hinders glucose utilization in sorafenib-treated breast cancer cells (24).